Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Might Be Temporarily Headed By Ostroff As Califf Sets His Departure

Executive Summary

Former acting commissioner in line for the temporary position again under FDA policy, unless incoming Trump administration designates someone else.


Related Content

US FDA’s OCI Director Is Leaving For Private Practice
Woodcock Tries To Calm US FDA Staff Fears About Trump
Possible Trump FDA Commish Candidate Favors (Much) Lighter Touch
'Brilliant' and 'Steady' Jenkins Retiring From US FDA's Office of New Drugs
Will US FDA Wind Up With More Political Positions Under Trump?
Gottlieb Joins HHS Transition Team; Will Next Stop Be FDA?
Califf Maintains Desire To Stay At FDA, But Would Either Presidential Candidate Keep Him?
FDA Chief Scientist Post A Chance For Califf To Make Mark
FDA Feels Heat On Drug Pricing And Generic Labeling Rule
FDA Staying The Course Under Ostroff; Hamburg’s Concerns Will Remain Focus


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts